PRHB Pure H2O Bio Technologies Inc New (CE)

Pure H20 Bio-Technologies, Inc. (Pink Sheets:PRHB), today announces confirmation of New Stock Symbol PRHB and Reverse Split of its Common Stock. The Company�s stock transfer agent, Continental Stock Transfer and Trust Company, located at 17 Battery Place, New York, New York, is the Exchange Agent for its approved reverse split of the Company's Common Stock. On March 3, 2008 the company filed a 1-for-4,500 (1:4,500) reverse stock split of the Company's Common Stock. The reverse split became effective today upon the filing of the company's Certificate of Amendment to the Articles of Incorporation of Pure H20 Bio-Technologies, Inc., with the Florida Secretary of State. The reorganization will be effective at the open of the market today and the new stock symbol is "PRHB" and the Cusip Number is: 746223 40 3. The distribution of the post-split common shares are payable upon surrender of the pre-split common shares. "For each forty-five hundred (4,500) shares of pre-split common stock held a shareholder will receive one (1) share of post-split common stock. No fractional shares or script representing fractions of a share shall be issued, but in lieu thereof, each fraction of a share that any Stockholder would otherwise be entitled to receive shall be rounded up to the nearest whole share and no additional script or payment made," as stated in the Company's Articles of Amendment. About PRHB: PRHB is a publicly held company specializing in the research, development and commercialization of its unique residential, commercial and hospital water disinfection systems. The company intends to commence the manufacture and distribution of its products through a network of independent distributors. The foregoing press release contains forward-looking statements that can be identified by such terminology as expects, potential, suggests, may, intends, or similar expressions. Such forward-looking statements involve known risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management expectations regarding future research, development, and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing, unexpected regulatory delays or government regulation generally, the company's ability to obtain or maintain patent and other proprietary intellectual protection, and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. For more information visit Investor Relations at www.pureh20biotech.com.